Illumina (NASDAQ:ILMN) Updates FY 2021 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY 2021 earnings guidance on Thursday. The company provided earnings per share guidance of $5.500-$5.600 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.730. The company issued revenue guidance of $4.41 billion-$4.41 billion, compared to the consensus revenue estimate of $4.35 billion.

Several analysts have recently weighed in on the company. Canaccord Genuity lifted their price objective on Illumina from $515.00 to $555.00 and gave the stock a buy rating in a report on Monday, August 9th. Robert W. Baird decreased their price target on Illumina from $493.00 to $437.00 and set a neutral rating on the stock in a research note on Monday, November 8th. Zacks Investment Research lowered Illumina from a hold rating to a strong sell rating and set a $390.00 price target on the stock. in a research note on Tuesday, October 19th. TheStreet lowered Illumina from a b- rating to a c rating in a research note on Wednesday, October 6th. Finally, Piper Sandler boosted their price target on Illumina from $510.00 to $560.00 and gave the company an overweight rating in a research note on Friday, August 6th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. According to, Illumina currently has a consensus rating of Hold and an average price target of $424.00.

ILMN stock opened at $369.79 on Friday. The company has a market cap of $57.80 billion, a P/E ratio of 60.72, a PEG ratio of 2.09 and a beta of 0.86. Illumina has a twelve month low of $304.01 and a twelve month high of $555.77. The company has a quick ratio of 2.24, a current ratio of 2.68 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average of $402.70 and a 200-day moving average of $439.67.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, November 4th. The life sciences company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.21. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.04 billion. Illumina had a return on equity of 15.03% and a net margin of 21.17%. The firm’s quarterly revenue was up 39.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.02 earnings per share. As a group, equities research analysts anticipate that Illumina will post 5.61 earnings per share for the current fiscal year.

In related news, SVP Alexander Aravanis sold 2,926 shares of the stock in a transaction that occurred on Tuesday, October 12th. The stock was sold at an average price of $409.21, for a total transaction of $1,197,348.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Susan H. Tousi sold 300 shares of the company’s stock in a transaction that occurred on Monday, August 30th. The shares were sold at an average price of $463.50, for a total value of $139,050.00. Following the completion of the sale, the senior vice president now owns 41,456 shares in the company, valued at approximately $19,214,856. The disclosure for this sale can be found here. Insiders sold 14,507 shares of company stock valued at $6,001,240 in the last quarter. 0.23% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Featured Story: Percentage Gainers

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with's FREE daily email newsletter.